A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
PHASE1CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
June 26, 2024
Primary Completion Date
August 7, 2024
Study Completion Date
August 7, 2024
Conditions
Healthy
Interventions
DRUG
[14C]MK-1084
Oral administration
Trial Locations (1)
53704
Fortea CRU Madison (Site 0001), Madison
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT06687759 - A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006) | Biotech Hunter | Biotech Hunter